Exosomes vs PRP for Hair Loss: What the Evidence Shows Clinicians

Part of the PRO EXO Professional Series — clinical-grade exosome vials for hair transplant surgeons, dermatologists, and aesthetic clinics.

Platelet-rich plasma has been a mainstay of in-clinic hair loss treatment for over a decade. More recently, exosome-based scalp therapy has moved from research labs into aesthetic and trichology practices across Singapore, Malaysia, and Indonesia. For a clinic deciding where to invest chair time and capital, the question is practical: when does the choice between exosome and PRP hair loss clinic treatment favour one over the other?

This article compares the two on mechanism, the current state of the evidence, practical workflow, and cost-per-session — written for the clinician evaluating a supplier, not the retail patient.

The core difference in mechanism

PRP works by concentrating a patient's own platelets and the growth factors they release — PDGF, VEGF, TGF-β, IGF-1 and others — then reintroducing them to the scalp to signal the follicle. Its strength is autologous safety; its limitation is variability. The yield depends on the patient's blood, their platelet count on the day, the centrifugation protocol, and the operator. Two sessions on two patients are rarely identical.

Exosomes take a different route. They are nanoscale extracellular vesicles that carry a standardised cargo of signalling molecules: growth factors, cytokines, lipids, and microRNA. Because exosome products are manufactured rather than spun from the patient, the signal is consistent batch to batch. There is no blood draw, no centrifuge step, and no patient-dependent yield.

In short: PRP delivers the patient's own signal at variable concentration; exosomes deliver a standardised, cell- or plant-derived signal off the shelf. Both aim to influence the same follicular pathways — promoting the anagen phase, supporting dermal papilla activity, and improving the perifollicular environment.

What the evidence currently shows

It is important to be precise here, because clinicians will be asked by patients. PRP for androgenetic alopecia has the larger and longer evidence base — multiple controlled studies and meta-analyses report improvements in density and thickness versus placebo, though results vary with protocol and patient selection. PRP is best understood as an established adjunct with moderate-quality supporting evidence.

Exosome therapy for hair is newer. The mechanistic rationale is strong and early clinical reports are encouraging, but the body of large, randomised, peer-reviewed human trials is still developing. Honest positioning matters: exosomes are a promising, rapidly maturing modality rather than a settled standard of care. The defensible summary for a patient conversation is that PRP is the better-studied option, while exosomes offer a standardised, off-the-shelf signal and a more comfortable session, with a still-growing evidence base.

Practical workflow in the chair

PRP requires a blood draw, centrifugation, and preparation before application — typically adding 20–30 minutes per session and requiring phlebotomy capability and a centrifuge. It is inherently a single-patient, same-day process.

Exosome vials are ready to use. There is no draw and no spin; the product is applied topically immediately after micro-channelling or alongside a delivery device. This shortens the appointment, removes the centrifuge bottleneck, and lets less specialised staff support the session under supervision. Both modalities are commonly paired with a delivery device — microneedling, electroporation, or roller systems — to improve penetration past the stratum corneum.

Cost-per-session and margin

PRP's consumable cost is low, but its chair-time cost is high because of the draw-and-spin workflow, and capital is tied up in a centrifuge. Exosome vials carry a higher per-unit consumable cost but lower chair-time cost and no centrifuge capital. Margin therefore depends on your clinic's throughput and pricing model rather than on one modality being universally cheaper.

A modular exosome system changes this further: rather than one fixed formula, the treatment can be tailored — a barrier-repair vial for a post-transplant patient, a microbiome/sebum vial for a seborrheic scalp, a regeneration vial for androgenetic thinning — so a single inventory serves multiple indications.

Can you combine them?

Yes — and many clinics do. PRP and exosomes are not mutually exclusive; some protocols layer a standardised exosome signal on top of an autologous PRP base, particularly for patients who want a more intensive course. The decision should be clinical and patient-specific rather than driven by supplier marketing.

So which should a clinic choose?

There is no single answer, and any supplier who gives you one is selling rather than advising. Choose PRP when the patient prioritises a fully autologous treatment, when the evidence base is the deciding factor, and when your clinic already runs phlebotomy and centrifuge workflows smoothly.

Choose exosome therapy when you want batch-consistent dosing, a faster and more comfortable session, higher throughput, and the flexibility to match the formula to the indication. Or offer both as a tiered menu — PRP as the established option, exosomes as the premium, device-paired upgrade.

Where Ossome PRO EXO fits

Ossome's PRO EXO Series is a clinic-exclusive, Singapore-made, plant-derived exosome scalp range designed for professional use with microneedling, electroporation, and roller systems. A note on how we position it: Ossome does not compete on exosome count. The number of vesicles in a vial is a marketing metric, not a clinical one — what matters is purity, quality, and the blend of biologics, and a plant-derived source that is the most ethical and legal option for scalp use across our markets. The modular TrichoCare system then lets clinics build custom protocols across three specialist lines rather than relying on a single fixed formula.